Furthermore, combined treatment with OXA and IRX4 overexpression significantly reduced the levels of EGFR and the phosphorylationlevels of EGFR downstream signaling molecules.<h4>Conclusion</h4>These findings suggest that IRX4 may be a prognostic biomarker and therapeutic target in CRC. Here, EGFR is linked to colorectal carcinoma.